GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turnstone Biologics Corp (NAS:TSBX) » Definitions » Pretax Margin %

TSBX (Turnstone Biologics) Pretax Margin % : % (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Turnstone Biologics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Turnstone Biologics's Pre-Tax Income for the three months ended in Dec. 2024 was $-12.04 Mil. Turnstone Biologics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Turnstone Biologics's pretax margin for the quarter that ended in Dec. 2024 was %.

The historical rank and industry rank for Turnstone Biologics's Pretax Margin % or its related term are showing as below:


TSBX's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -129.77
* Ranked among companies with meaningful Pretax Margin % only.

Turnstone Biologics Pretax Margin % Historical Data

The historical data trend for Turnstone Biologics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turnstone Biologics Pretax Margin % Chart

Turnstone Biologics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Pretax Margin %
33.27 -41.87 -287.40 -

Turnstone Biologics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Turnstone Biologics's Pretax Margin %

For the Biotechnology subindustry, Turnstone Biologics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Turnstone Biologics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turnstone Biologics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Turnstone Biologics's Pretax Margin % falls into.


;
;

Turnstone Biologics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Turnstone Biologics's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-70.8/0
= %

Turnstone Biologics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-12.037/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turnstone Biologics  (NAS:TSBX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Turnstone Biologics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Turnstone Biologics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Turnstone Biologics Business Description

Traded in Other Exchanges
N/A
Address
9310 Athena Circle, Suite 300, La Jolla, CA, USA, 92037
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Executives
Davis Jerel director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert J Gould director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Sammy J. Farah director, officer: President & CEO C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Saryah Azmat officer: Chief Business Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Venkat Ramanan officer: Chief Financial Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Campisi Peter Joseph Jr. officer: Chief Legal Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Vijay Chiruvolu officer: Int. Chief Technology Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kanya Rajangam director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Versant Ventures V Gp-gp (canada), Inc. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Michael F. Burgess director, officer: Interim Chief Medical Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stewart Abbot officer: Chief Scientific Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037